JP2024533485A5 - - Google Patents
Info
- Publication number
- JP2024533485A5 JP2024533485A5 JP2024516380A JP2024516380A JP2024533485A5 JP 2024533485 A5 JP2024533485 A5 JP 2024533485A5 JP 2024516380 A JP2024516380 A JP 2024516380A JP 2024516380 A JP2024516380 A JP 2024516380A JP 2024533485 A5 JP2024533485 A5 JP 2024533485A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cdr
- self
- ferritin
- differs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163243372P | 2021-09-13 | 2021-09-13 | |
| US63/243,372 | 2021-09-13 | ||
| PCT/CA2022/051361 WO2023035084A1 (en) | 2021-09-13 | 2022-09-13 | Dr5-targeting multabodies for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533485A JP2024533485A (ja) | 2024-09-12 |
| JP2024533485A5 true JP2024533485A5 (https=) | 2025-09-22 |
Family
ID=85507784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516380A Pending JP2024533485A (ja) | 2021-09-13 | 2022-09-13 | がんの治療のためのＤＲ５標的化Ｍｕｌｔａｂｏｄｙ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240409652A1 (https=) |
| EP (1) | EP4401790A4 (https=) |
| JP (1) | JP2024533485A (https=) |
| KR (1) | KR20240101550A9 (https=) |
| CN (1) | CN118317980A (https=) |
| AU (1) | AU2022344813A1 (https=) |
| CA (1) | CA3231176A1 (https=) |
| MX (1) | MX2024003139A (https=) |
| WO (1) | WO2023035084A1 (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020320459A1 (en) * | 2019-08-01 | 2022-03-03 | The Governing Council Of The University Of Toronto | Multi-valent and multi-specific nanoparticle platforms and methods |
| WO2022109743A1 (en) * | 2020-11-25 | 2022-06-02 | The Hospital For Sick Children | Polypeptides targeting dr4 and/or dr5 and related compositions and methods |
-
2022
- 2022-09-13 KR KR1020247011876A patent/KR20240101550A9/ko active Pending
- 2022-09-13 AU AU2022344813A patent/AU2022344813A1/en active Pending
- 2022-09-13 EP EP22868435.3A patent/EP4401790A4/en active Pending
- 2022-09-13 JP JP2024516380A patent/JP2024533485A/ja active Pending
- 2022-09-13 CN CN202280062080.6A patent/CN118317980A/zh active Pending
- 2022-09-13 MX MX2024003139A patent/MX2024003139A/es unknown
- 2022-09-13 WO PCT/CA2022/051361 patent/WO2023035084A1/en not_active Ceased
- 2022-09-13 CA CA3231176A patent/CA3231176A1/en active Pending
- 2022-09-13 US US18/691,258 patent/US20240409652A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12247074B2 (en) | Antibody molecules | |
| JP2021503455A5 (https=) | ||
| JP2022544771A5 (https=) | ||
| WO2019091436A1 (zh) | 4-1bb抗体及其制备方法和应用 | |
| TW201930338A (zh) | 抗ｃｄ３８抗體及其使用方法 | |
| JP2022535924A5 (https=) | ||
| CN117143247A (zh) | 双特异性蛋白质及其制备方法 | |
| NZ717476A (en) | Anti-garp protein and uses thereof | |
| JP2022512234A5 (https=) | ||
| JP2018509901A (ja) | Ｈｂｖ感染および関連症状を治療するための三重特異的結合分子 | |
| JP2018093875A5 (https=) | ||
| WO2023186120A1 (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| JP2025063183A5 (https=) | ||
| JP2026004299A5 (https=) | ||
| US20230192861A1 (en) | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | |
| CA3173414A1 (en) | Pd-1 agonist multimeric binding molecules | |
| CN112074541A (zh) | Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白 | |
| CN101189265B (zh) | 抗il2抗体 | |
| JP2024532489A5 (https=) | ||
| CN115397852A (zh) | 工程化抗il-2抗体 | |
| JP2022538222A5 (https=) | ||
| JP2025160226A5 (https=) | ||
| AR114436A1 (es) | Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas | |
| JP2025541367A (ja) | 多価および多重特異性サイトカインアンタゴニスト | |
| WO2023125561A1 (zh) | 靶向tigit的抗体和双特异性抗体及其应用 |